Investors News Releases Sign up for email alerts to receive company and investor updates News Releases Investor Relations Investor Relations News Releases Presentations & Events Common Stock Information Stock Quote & Chart Analyst Coverage SEC Filings Corporate Governance Overview Board of Directors Committee Composition Management Team Annual Reports News Releases Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Dec 05 2024 Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs Nov 14 2024 Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds Nov 13 2024 Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds Nov 12 2024 Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update Oct 24 2024 Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule Oct 23 2024 Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium Oct 09 2024 Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium Sep 25 2024 Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study Sep 04 2024 Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference Sep 03 2024 Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter Aug 14 2024 Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update Aug 07 2024 Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results Jun 26 2024 Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions Jun 04 2024 Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting Jun 03 2024 Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for Cancer May 14 2024 Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update May 08 2024 Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results May 02 2024 Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules Apr 30 2024 Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules Apr 01 2024 Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer Mar 19 2024 Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Mar 13 2024 Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results Mar 07 2024 Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 Mar 06 2024 Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit Feb 20 2024 Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last » Toolkit Email AlertsRSS FeedsPrint Page
News Releases Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Dec 05 2024 Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs Nov 14 2024 Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds Nov 13 2024 Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds Nov 12 2024 Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update Oct 24 2024 Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule Oct 23 2024 Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium Oct 09 2024 Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium Sep 25 2024 Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study Sep 04 2024 Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference Sep 03 2024 Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter Aug 14 2024 Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update Aug 07 2024 Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results Jun 26 2024 Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions Jun 04 2024 Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting Jun 03 2024 Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for Cancer May 14 2024 Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update May 08 2024 Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results May 02 2024 Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules Apr 30 2024 Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules Apr 01 2024 Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer Mar 19 2024 Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Mar 13 2024 Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results Mar 07 2024 Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 Mar 06 2024 Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit Feb 20 2024 Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
Dec 05 2024 Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs
Nov 14 2024 Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds
Nov 12 2024 Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
Oct 24 2024 Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule
Oct 23 2024 Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
Oct 09 2024 Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
Sep 25 2024 Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study
Sep 04 2024 Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference
Sep 03 2024 Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter
Aug 14 2024 Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update
Jun 26 2024 Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions
Jun 04 2024 Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting
Jun 03 2024 Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for Cancer
May 14 2024 Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update
May 02 2024 Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules
Apr 30 2024 Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Apr 01 2024 Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer
Mar 19 2024 Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Mar 07 2024 Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
